close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BillionToOne, Inc. - Class A common stock (NQ:BLLN)

110.24 -1.76 (-1.57%)
Delayed Quote Updated: 3:58 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BillionToOne, Inc. - Class A common stock

< Previous 1 2 Next >
News headline image
BillionToOne (BLLN) Q3 2026 Earnings Call Transcript ↗
Record revenue, a fifth profitable quarter, and a December cancer test launch. 
Via The Motley Fool
Topics Earnings
News headline image
Billiontoone Q3 Earnings Call Highlights ↗
Billiontoone (NASDAQ:BLLN) raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics... 
Via MarketBeat
Topics Earnings
BillionToOne Inc Cl A (NASDAQ:BLLN) Tops Q3 2026 Estimates and Raises Revenue Outlook ↗
Via Chartmill
News headline image
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
From BillionToOne, Inc.
Via GlobeNewswire
BillionToOne (NASDAQ:BLLN) Shares Tumble After Q2 Profit Misses Estimates ↗
Via Chartmill
BillionToOne (NASDAQ:BLLN) Blows Past Q1 Estimates, Raises Full-Year Outlook ↗
Via Chartmill
BillionToOne Inc (NASDAQ:BLLN) Q4 Earnings Soar, Company Raises 2026 Revenue Outlook ↗
Via Chartmill
News headline image
BillionToOne to Participate in Two Upcoming Investor Conferences
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response 
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
BillionToOne SVP Sells 1,416 Shares ↗
John Roderick Ten Bosch sold shares on Sept. 9, maintaining a direct stake worth ~$2.4 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million ↗
The medical diagnostics company disclosed a substantial insider stock sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million ↗
The molecular diagnostics company reported a notable insider stock sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BillionToOne (BLLN) Q2 2026 Earnings Call Transcript ↗
Oncology tests surged 176% while prenatal revenue climbed 55%, driving 64% overall growth. 
Via The Motley Fool
Topics Earnings
Top stock movements in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
Billiontoone Q2 Earnings Call Highlights ↗
Billiontoone (NASDAQ:BLLN) reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses.... 
Via MarketBeat
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
A BillionToOne Insider Sold 801 Shares as Revenue Jumped 84% ↗
Nancy Johnson liquidated 801 shares via a pre-established Rule 10b5-1 plan, retaining a $2.6 million stake in the molecular diagnostics firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tom Gardner's Five Stocks for the Long Term: Big Diversification, AI Research, and Caution ↗
Tom Gardner makes the case for fifty-stock portfolios and AI-powered research, then names five companies to consider owning for the next five-plus years. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million ↗
This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BillionToOne (BLLN) Q1 2026 Earnings Transcript ↗
BillionToOne (BLLN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
From BillionToOne, Inc.
Via GlobeNewswire
News headline image
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
From BillionToOne, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.